Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ENB Therapeutics, Inc.

ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023
From ENB Therapeutics, Inc.
Via Business Wire
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023
From ENB Therapeutics, Inc.
Via Business Wire
ENB Therapeutics to present at the 2023 BIO CEO & Investor and Immuno-Oncology 360o Conferences
From ENB Therapeutics, Inc.
Via Business Wire
ENB Therapeutics to Present at SVB Securities Biopharma Private Company Connect on July 20-21, 2022
From ENB Therapeutics, Inc.
Via AccessWire
ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer
From ENB Therapeutics, Inc.
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.